University of Colorado Cancer Center genetically sequences most common bladder cancer

(Press-News.org) August 11, 2011 (Aurora, CO)--In an article published online this week in Nature Genetics, a University of Colorado Cancer Center team in partnership with universities in China and Denmark reports the first genetic sequencing of urothelial (transitional) carcinoma, the most prevalent type of bladder cancer.

Recognizing the genetic mutations that make bladder cancer cells different than their healthy neighbors may allow early genetic screenings for cancer and new therapies targeting cells with these mutations. In addition, the mutations the team found are similar to those recently discovered in a host of other cancers, implying a possible common denominator in the cause of cancer in general. Specifically, in 59 percent of 97 patients with urothelial carcinoma, the team found mutations in genes responsible for chromatin remodeling – the process of packaging DNA for easy duplication during cell division.

"The discovery of mutation in the UTX gene and seven similar chromatin remodeling genes is a major step toward genetic testing and treatment of bladder cancer," says Dan Theodorescu, MD, PhD, director the University of Colorado Cancer Center and an author on this work. On a grand scale, the study also provides the first-ever overview of the genetic basis of urothelial bladder cancer and implicates chromatin remodeling in its cause.

Chromatin describes the genetic contents of a cell's nucleus including the cell's DNA and the proteins that sculpt its arrangement inside the cell. During most of a cell's life, these proteins arrange DNA loosely so that its inner parts are accessible and available for use. In preparation for cell division, these proteins in the cell's chromatin constrict DNA into a tight package for efficient duplication. This squeezing is known as "chromatin remodeling." How the cell remodels and thus how it duplicates depends greatly on associated chromatin remodeling genes -- the genes this study found to be mutated in many bladder cancer patients.

"When we talk about 'causes' of cancer, there's a black box between a healthy cell and the emergence of cancerous ones," says Theodorescu. "By exploring the genetic changes that take place inside this box, we can look at the links of the chain of events that lead to cancer and hopefully target specific links for therapy."

In the development of bladder cancer, this study shows that chromatin remodeling is an important link.

"We are currently well underway in performing similar sequencing with Caucasian subjects to determine if the mutations in the Caucasian population are similar to those seen in this study's Asian subjects," Theodorescu says.

After confirmation, the task will be twofold: designing genetic tests for these mutations that may allow easy, early, accurate diagnosis of bladder cancer, and developing therapies that recognize these mutations and kill the cancerous cells that hold them.

### Dan Theodorescu is the Paul Bunn Chair of Cancer Research and professor of surgery and pharmacology at the University of Colorado School of Medicine.

About the University of Colorado Cancer Center

Colorado's only NCI-designated comprehensive cancer center

The University of Colorado Cancer Center is Colorado's only National Cancer Institute-designated comprehensive cancer center. Headquartered on the University of Colorado Anschutz Medical Campus, the CU Cancer Center is a consortium of three state universities and six institutions. Together, our more than 435 members are committed to transforming cancer research in the state of Colorado by creating an interdisciplinary nexus of clinicians and scientists who will discover, develop and deliver breakthroughs to prevent and treat cancer in Colorado and around the world.

Learn more at www.coloradocancercenter.org.

This work was supported by grants from the National High Technology Research and Development Program of China (863 Program, 2006AA02A302 to H.Y. 2009AA022707 to X.Z.), the Promotion Program for Shenzhen Key Laboratory, Shenzhen, China (CXB200903090055A and CXB201005250016A to Z.C.), and Research Fund for the Doctoral Program of Higher Education of China (20100001110100).